Danish pharmaceutical company Novo Nordisk has announced a significant price reduction across all strengths of Wegovy, its groundbreaking once-weekly injectable medication for chronic weight management.

The company said the decision was made to make the drug more accessible to a broader section of people living with obesity and overweight, conditions that affect millions of Indians and are increasingly being recognised as chronic, lifestyle-related diseases rather than aesthetic concerns.

NEW COST OF WEGOVY

Under the revised pricing, the starting dose of Wegovy (0.25 mg) will now cost Rs 2,712 per week, a substantial cut that Novo Nordisk says reflects its commitment to patient-centric healthcare.

The company first launched Wegovy in India in June 2025 and sold insulin in their tradema

See Full Page